New blood test 'can better detect severe forms of prostate cancer'

9 October 2012

The most aggressive prostate cancers could soon be detected through an innovative blood test, researchers claim.

Scientists from London's Institute of Cancer Research believe that the procedure could determine the most severe forms of the life-threatening disease with genetic results which read like a barcode.

The unique blood test works by identifying the signature pattern of genes that are switched on and off in blood cells triggered by a prostate cancer tumour.

Researchers have already trialled the procedure on 94 patients, in which they were capable of splitting the individuals into four distinct groups depending on their results.

Moving forward, Professor Malcolm Mason, of Cancer Research UK, said: "If the present results are borne out in further studies, we may have a new way of selecting the right treatments for the right patients."

Cancer Research UK has found in its own study recently that more than 40,000 men were diagnosed with prostate cancer in 2009 alone, underlining the major health problem surrounding the disease at the moment.

Posted by Philip Briggs


Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare

Find a treatment, test or scan available at:

or

Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.

or

Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...

Categories

Cancer

© Spire Healthcare Group plc (2016)